Stocks and Investing Stocks and Investing
Thu, February 29, 2024

Gena Wang Maintained (SRPT) at Buy with Increased Target to $185 on, Feb 29th, 2024


Published on 2024-10-28 09:19:14 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $141 to $185 on, Feb 29th, 2024.

Gena has made no other calls on SRPT in the last 4 months.



There are 7 other peers that have a rating on SRPT. Out of the 7 peers that are also analyzing SRPT, 1 agrees with Gena's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Gavin Clark-Gartner of "Evercore ISI Group" Maintained at Hold with Increased Target to $138 on, Tuesday, February 20th, 2024


These are the ratings of the 6 analyists that currently disagree with Gena


  • Andreas Argyrides of "Wedbush" Reiterated at Buy and Held Target at $224 on, Tuesday, February 20th, 2024
  • Uy Ear of "Mizuho" Maintained at Strong Buy with Increased Target to $145 on, Wednesday, February 14th, 2024
  • Kostas Biliouris of "BMO Capital" Initiated at Buy and Held Target at $170 on, Wednesday, January 31st, 2024
  • Neena Bitritto-Garg of "Deutsche Bank" Initiated at Strong Buy and Held Target at $109 on, Tuesday, December 12th, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $146 on, Tuesday, October 31st, 2023
  • Anupam Rama of "JP Morgan" Maintained at Buy with Decreased Target to $115 on, Tuesday, October 31st, 2023
Contributing Sources